We are live on ! Find out more
TMCI icon

Treace Medical Concepts

134 hedge funds and large institutions have $230M invested in Treace Medical Concepts in 2024 Q3 according to their latest regulatory filings, with 29 funds opening new positions, 36 increasing their positions, 49 reducing their positions, and 21 closing their positions.

New
Increased
Maintained
Reduced
Closed

38% more first-time investments, than exits

New positions opened: 29 | Existing positions closed: 21

6% more funds holding

Funds holding: 127134 (+7)

0.31% less ownership

Funds ownership: 64.03%63.72% (-0.31%)

7% less call options, than puts

Call options by funds: $2.56M | Put options by funds: $2.74M

13% less capital invested

Capital invested by funds: $264M → $230M (-$34.3M)

27% less repeat investments, than reductions

Existing positions increased: 36 | Existing positions reduced: 49

Holders
134
Holders Change
+7
Holders Change %
+5.51%
% of All Funds
1.92%
Holding in Top 10
Holding in Top 10 Change
Holding in Top 10 Change %
% of All Funds
New
29
Increased
36
Reduced
49
Closed
21
Calls
$2.56M
Puts
$2.74M
Net Calls
-$187K
Net Calls Change
-$32K
Name Holding Trade Value Shares
Change
Change in
Stake
AC
1
Armistice Capital
New York
$35.9M +$5.37M +836,000 +16%
BlackRock
2
BlackRock
New York
$24.3M +$730K +113,654 +3%
Morgan Stanley
3
Morgan Stanley
New York
$19M +$2.85M +443,027 +16%
Vanguard Group
4
Vanguard Group
Pennsylvania
$15.9M -$5.67M -883,406 -24%
William Blair Investment Management
5
William Blair Investment Management
Illinois
$13.9M -$8.28M -1,289,657 -35%
Deutsche Bank
6
Deutsche Bank
Germany
$11.9M +$59.3K +9,240 +0.5%
CIBC Private Wealth Group
7
CIBC Private Wealth Group
Georgia
$11M -$255K -39,750 -2%
GS
8
Gagnon Securities
New York
$10.3M +$8.26M +1,286,582 +266%
JP Morgan Chase
9
JP Morgan Chase
New York
$7.32M +$5.53M +861,689 +215%
D.E. Shaw & Co
10
D.E. Shaw & Co
New York
$6.64M +$2.46M +382,797 +50%
Geode Capital Management
11
Geode Capital Management
Massachusetts
$6.04M -$138K -21,413 -2%
State Street
12
State Street
Massachusetts
$5.79M +$256K +39,907 +4%
SCM
13
Soleus Capital Management
Connecticut
$5.15M -$9.49M -1,477,707 -62%
Goldman Sachs
14
Goldman Sachs
New York
$3.86M +$2.67M +416,060 +167%
Millennium Management
15
Millennium Management
New York
$3.22M -$845K -131,520 -19%
KCM
16
Kornitzer Capital Management
Kansas
$3.06M
GA
17
Gagnon Advisors
New York
$2.84M +$3.15M +489,891 New
Northern Trust
18
Northern Trust
Illinois
$2.66M +$498K +77,478 +20%
Marshall Wace
19
Marshall Wace
United Kingdom
$2.48M -$233K -36,309 -8%
N
20
Nuveen
North Carolina
$2.46M +$1.61M +250,126 +144%
Charles Schwab
21
Charles Schwab
California
$2.27M +$114K +17,783 +5%
Norges Bank
22
Norges Bank
Norway
$2.13M
CSS
23
Cubist Systematic Strategies
Connecticut
$1.81M +$2M +312,090 New
TI
24
Trexquant Investment
Connecticut
$1.73M +$1.65M +256,125 +613%
Wealth Enhancement Advisory Services
25
Wealth Enhancement Advisory Services
Minnesota
$1.4M -$373 -58 -0%

TMCI Hedge Fund Activity: Q3 2024 in Review

134 of the 6,964 institutional investors tracked by Wall St. Rank reported a position in Treace Medical Concepts (TMCI) for Q3 2024, worth a combined $230M — down 13% from $264M a quarter earlier.

Buyers outnumbered sellers: 29 funds opened new TMCI positions and 21 closed out — a net gain of 8 holders — while 36 added to existing stakes and 49 trimmed.

The largest buyer was Gagnon Securities, adding an estimated $8.26M. The largest seller was Soleus Capital Management, cutting an estimated $9.49M.

  • 134 institutional investors held Treace Medical Concepts (TMCI) as of Q3 2024, up from 127 in Q2 2024.
  • Funds reported $230M of Treace Medical Concepts stock for Q3 2024, down 13% quarter-over-quarter.
  • 29 funds opened new Treace Medical Concepts positions in Q3 2024 and 21 closed out, a net change of +8 holders.
  • The largest Treace Medical Concepts buyer in Q3 2024 was Gagnon Securities, an estimated $8.26M added.
  • The largest Treace Medical Concepts seller in Q3 2024 was Soleus Capital Management, an estimated $9.49M sold.

Based on aggregated 13F filings for Q3 2024.